“Inherent Conflict of Interest:” Cannabiz Slams DEA MED Proposal
Two influential cannabis advocacy groups say the federal government’s proposed rules to accelerate MED research would give too much control to U.S. Drug Enforcement Administration (DEA).
The National Cannabis Industry Association opposed the entire rulemaking, warning on May 11 that it would “radically overhaul how medical cannabis can be researched.”
NORML previously warned that the DEA's proposal could block research . . .
Log in or become a WeedWeek Member to read this article.
